Revelation Biosciences Key Executives
This section highlights Revelation Biosciences's key executives, including their titles and compensation details.
Find Contacts at Revelation Biosciences
(Showing 0 of )
Revelation Biosciences Earnings
This section highlights Revelation Biosciences's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.
$2.92
Stock Price
$2.64M
Market Cap
9
Employees
San Diego, CA
Location
Financial Statements
Access annual & quarterly financial statements for Revelation Biosciences, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $25.05K | $40.01K | $69.17K | $- |
| Gross Profit | $- | $-25.05K | $-40.01K | $-69.17K | $- |
| Gross Profit Ratio | 0.00% | - | - | - | 0.00% |
| Research and Development Expenses | $3.55B | $4.15M | $5.38M | $6.91M | $2.56M |
| General and Administrative Expenses | $4.43B | $4.51M | $5.49M | $5.04M | $1.23M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $144.26K |
| Selling General and Administrative Expenses | $4.43B | $4.51M | $5.49M | $5.04M | $145.49K |
| Other Expenses | $- | $- | $34.96K | $-36.35K | $- |
| Operating Expenses | $7.98B | $8.66M | $10.86M | $11.95M | $145.49K |
| Cost and Expenses | $- | $8.66M | $10.86M | $11.95M | $145.49K |
| Interest Income | $- | $- | $- | $- | $10.91K |
| Interest Expense | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $- | $25.05K | $40.01K | $69.17K | $3.80M |
| EBITDA | $-7.98B | $-95.21K | $-10.84M | $-11.93M | $-145.49K |
| EBITDA Ratio | - | - | - | - | - |
| Operating Income | $-7.98B | $-8.66M | $-10.86M | $-11.95M | $-145.49K |
| Operating Income Ratio | - | - | - | - | - |
| Total Other Income Expenses Net | $-7.06B | $8.54M | $34.96K | $-36.35K | $-1.49M |
| Income Before Tax | $-15.04B | $-120.25K | $-10.83M | $-11.99M | $-1.63M |
| Income Before Tax Ratio | - | - | - | - | - |
| Income Tax Expense | $- | $- | $-34.96K | $-219.78K | $-3.80K |
| Net Income | $-15.04B | $-120.25K | $-10.79M | $-11.99M | $-1.63M |
| Net Income Ratio | - | - | - | - | - |
| EPS | $-8768.31 | $-0.53 | $-600.77 | $-1275.02 | $-188.18 |
| EPS Diluted | $-8768.31 | $-0.53 | $-600.77 | $-1275.02 | $-188.18 |
| Weighted Average Shares Outstanding | 1.72M | 228.00K | 17.97K | 9.40K | 8.66K |
| Weighted Average Shares Outstanding Diluted | 1.72M | 228.64K | 17.97K | 9.40K | 8.66K |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $26.96K | $- | $- | $- | $37.57K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $13.48K | $- | $7.22K | $6.26K | $6.26K | $6.26K | $6.26K | $6.26K | $6.26K | $6.26K | $6.26K | $21.22K | $- | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit | $13.48K | $- | $-7.22K | $-6.26K | $31.31K | $-6.26K | $-6.26K | $-6.26K | $-6.26K | $-6.26K | $-6.26K | $-21.22K | $- | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit Ratio | 50.00% | 0.00% | - | - | 83.33% | - | - | - | - | - | - | - | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $3.55B | $830.98K | $1.39M | $717.58K | $1.06M | $1.65M | $909.28K | $525.27K | $339.97K | $381.57K | $975.58K | $3.68M | $2.67M | $1.53M | $1.16M | $1.56M | $2.02M | $- | $93.31K | $- |
| General and Administrative Expenses | $4.42B | $965.71K | $1.13M | $1.18M | $1.27M | $1.13M | $1.02M | $1.09M | $878.36K | $817.90K | $884.84K | $2.91M | $1.19M | $1.51M | $1.28M | $1.05M | $875.89K | $868 | $71.57K | $- |
| Selling and Marketing Expenses | $13.48K | $- | $-7.22K | $-6.26K | $-6.26K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $4.42B | $965.71K | $1.12M | $1.18M | $1.26M | $1.13M | $1.02M | $1.09M | $878.36K | $817.90K | $884.84K | $2.91M | $1.19M | $1.51M | $1.28M | $1.05M | $875.89K | $868 | $71.57K | $7.16K |
| Other Expenses | $- | $- | $-5.87M | $-847.72K | $54.78K | $56.96K | $61.62K | $34.11K | $- | $- | $25.73K | $-30.24K | $-3.44K | $-557 | $-27.71K | $-4.64K | $- | $- | $- | $- |
| Operating Expenses | $7.97B | $1.80M | $2.52M | $1.90M | $2.32M | $2.78M | $1.93M | $1.62M | $1.22M | $1.20M | $1.86M | $6.59M | $3.86M | $3.04M | $2.44M | $2.61M | $2.89M | $868 | $164.88K | $7.16K |
| Cost and Expenses | $7.97B | $1.80M | $2.52M | $1.90M | $2.33M | $2.78M | $1.93M | $1.62M | $1.22M | $1.20M | $1.86M | $6.59M | $3.86M | $3.04M | $2.44M | $2.61M | $2.89M | $868 | $164.88K | $7.16K |
| Interest Income | $- | $- | $- | $- | $- | $- | $- | $- | $- | $28.73K | $- | $- | $222 | $1.85K | $1.83K | $- | $- | $- | $- | $- |
| Interest Expense | $- | $- | $- | $- | $7.78M | $- | $- | $- | $- | $- | $- | $30.24K | $41.76K | $557 | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $-20.70K | $7.22K | $7.22K | $6.26K | $6.26K | $6.26K | $6.26K | $6.26K | $6.26K | $6.26K | $6.26K | $21.22K | $6.26K | $6.07K | $3.81K | $642 | $2.89M | $52.75K | $164.88K | $- |
| EBITDA | $-1.75M | $-1.79M | $-2.52M | $-1.90M | $-2.32M | $-2.77M | $-1.93M | $-1.61M | $-1.21M | $-1.19M | $-1.85M | $-6.58M | $-3.85M | $-3.04M | $-2.44M | $-2.61M | $126 | $-868 | $164.36K | $-7.16K |
| EBITDA Ratio | -6477.77% | - | - | - | -6173.49% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | $-7.97B | $-1.80M | $-2.52M | $-1.90M | $-2.33M | $-2.78M | $-1.93M | $-1.62M | $-1.22M | $-1.20M | $-1.86M | $-6.59M | $-3.86M | $-3.04M | $-2.44M | $-2.61M | $-2.89M | $-868 | $-164.88K | $-7.16K |
| Operating Income Ratio | -29553804.24% | - | - | - | -6190.16% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Other Income Expenses Net | $7.97B | $-444.88K | $-5.87M | $-779.29K | $122.99K | $149.52K | $484.86K | $7.78M | $10.74K | $28.73K | $25.73K | $-30.24K | $-3.44K | $-557 | $-27.71K | $-4.64K | $1.27M | $- | $- | $- |
| Income Before Tax | $-1.73M | $-2.24M | $-8.39M | $-2.68M | $-2.20M | $-2.63M | $-1.45M | $6.16M | $-1.21M | $-1.17M | $-1.83M | $-6.62M | $-3.86M | $-3.04M | $-2.47M | $-2.61M | $-2.89M | $-868 | $-164.88K | $-7.16K |
| Income Before Tax Ratio | -6400.09% | - | - | - | -5862.84% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax Expense | $2 | $- | $- | $-2 | $-2 | $-92.56K | $-423.24K | $-7.78M | $-6.23K | $-28.73K | $-25.73K | $30.24K | $-6.26K | $557 | $27.71K | $4.64K | $126 | $-52.75K | $- | $- |
| Net Income | $-15.03B | $-2.24M | $-8.39M | $-2.68M | $-2.20M | $-2.63M | $-1.45M | $13.94M | $-1.20M | $-1.14M | $-1.81M | $-6.65M | $-3.86M | $-3.04M | $-2.47M | $-2.61M | $-2.89M | $-868 | $-164.88K | $-7.16K |
| Net Income Ratio | -55723272.45% | - | - | - | -5862.84% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS | $-1.01 | $-0.84 | $-5.13 | $-2.46 | $-8.33 | $-12.52 | $-7.47 | $189.15 | $-52.78 | $-56.95 | $-125.94 | $-491.44 | $-486.32 | $-351.38 | $-285.03 | $-301.52 | $-334.06 | $-0.10 | $-18.83 | $-2.72 |
| EPS Diluted | $-1.01 | $-0.84 | $-5.13 | $-2.46 | $-8.33 | $-12.52 | $-7.47 | $133.34 | $-52.78 | $-56.95 | $-125.94 | $-491.44 | $-486.32 | $-351.38 | $-285.03 | $-301.52 | $-334.06 | $-0.10 | $-18.83 | $-2.72 |
| Weighted Average Shares Outstanding | 1.72M | 2.68M | 1.64M | 1.09M | 264.54K | 209.91K | 193.74K | 73.69K | 22.76K | 20.05K | 14.36K | 13.53K | 7.94K | 8.66K | 8.66K | 8.66K | 8.66K | 8.85K | 8.76K | 2.63K |
| Weighted Average Shares Outstanding Diluted | 1.72M | 2.68M | 1.64M | 1.09M | 264.54K | 209.91K | 193.74K | 104.53K | 22.76K | 20.05K | 14.36K | 13.53K | 7.94K | 8.66K | 8.66K | 8.66K | 8.66K | 8.85K | 8.76K | 2.63K |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $6.50M | $11.99M | $5.25M | $1.27M | $4.49M |
| Short Term Investments | $6.49B | $- | $- | $- | $525.29K |
| Cash and Short Term Investments | $6.50B | $11.99M | $5.25M | $1.27M | $4.49M |
| Net Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $66.70M | $155.82K | $160.30K | $637.34K | $128.00K |
| Total Current Assets | $6.57B | $12.15M | $5.41M | $1.91M | $4.62M |
| Property Plant Equipment Net | $56.33K | $65.08K | $90.13K | $130.14K | $- |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $73.51M |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $56.28M | $- | $- | $0 | $- |
| Total Non-Current Assets | $56.33M | $65.08K | $90.13K | $130.14K | $73.51M |
| Other Assets | $- | $- | $-0 | $- | $-73.51M |
| Total Assets | $6.62B | $12.21M | $5.50M | $2.04M | $4.62M |
| Account Payables | $783.62K | $1.36M | $554.21K | $596.26K | $865.90K |
| Short Term Debt | $- | $- | $- | $16.75K | $- |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $2.91M | $- | $- |
| Other Current Liabilities | $1.13M | $4.20M | $3.90M | $1.53M | $342.88K |
| Total Current Liabilities | $1.91M | $5.56M | $4.45M | $2.14M | $1.21M |
| Long Term Debt | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- |
| Total Non-Current Liabilities | $- | $- | $554.21K | $2.91M | $2.91M |
| Other Liabilities | $- | $- | $-554.21K | $-2.91M | $-2.91M |
| Total Liabilities | $1.91B | $5.56M | $4.45M | $2.14M | $1.21M |
| Preferred Stock | $- | $- | $- | $7.48M | $403.73K |
| Common Stock | $522 | $265 | $683 | $2.31K | $2.29K |
| Retained Earnings | $-40.51B | $-25.47M | $-25.35M | $-14.52M | $-2.53M |
| Accumulated Other Comprehensive Income Loss | $- | $-0 | $- | $-0 | $- |
| Other Total Stockholders Equity | $45.21B | $32.11M | $26.40M | $14.42M | $5.54M |
| Total Stockholders Equity | $4.71B | $6.65M | $1.05M | $-99.47K | $3.41M |
| Total Equity | $4.71B | $6.65M | $1.05M | $-99.47K | $3.41M |
| Total Liabilities and Stockholders Equity | $6.62B | $12.21M | $5.50M | $2.04M | $4.62M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $6.62B | $12.21M | $5.50M | $2.04M | $4.62M |
| Total Investments | $6.49B | $- | $- | $- | $525.29K |
| Total Debt | $- | $- | $- | $16.75K | $- |
| Net Debt | $-6.50M | $-11.99M | $-5.25M | $-1.26M | $-4.49M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $6.50M | $6.54M | $12.07M | $14.55M | $11.99M | $13.99M | $15.71M | $17.70M | $5.25M | $6.20M | $3.48M | $7.19M | $1.27M | $4.14M | $6.37M | $73.51M | $4.49M | $3.32M |
| Short Term Investments | $6.49B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $19.75K | $301.72K | $390.65K | $525.29K | $- |
| Cash and Short Term Investments | $6.50B | $6.54M | $12.07M | $14.55M | $11.99M | $13.99M | $15.71M | $17.70M | $5.25M | $6.20M | $3.48M | $7.19M | $1.27M | $4.14M | $301.72K | $390.65K | $4.49M | $3.32M |
| Net Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $66.70M | $117.85K | $194.53K | $75.78K | $155.82K | $152.64K | $250.01K | $332.39K | $160.30K | $515.90K | $987.98K | $1.30M | $637.34K | $1.56M | $71.92K | $124.51K | $242.27K | $177.75K |
| Total Current Assets | $6.57B | $6.66M | $12.20M | $14.62M | $12.08M | $14.15M | $15.96M | $18.04M | $5.41M | $6.51M | $4.05M | $7.87M | $1.91M | $5.70M | $373.64K | $515.16K | $4.62M | $3.50M |
| Property Plant Equipment Net | $56.33K | $81.24K | $70.77K | $77.99K | $65.08K | $71.35K | $77.61K | $83.87K | $90.13K | $96.39K | $102.66K | $108.92K | $130.14K | $167.20K | $187.62K | $- | $- | $- |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $48.30M | $73.52M | $73.51M | $73.51M | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $56.28M | $- | $- | $- | $71.13K | $0 | $-0 | $-0 | $- | $0 | $-0 | $- | $-48.30M | $-73.52M | $-187.62K | $- | $73.51M | $- |
| Total Non-Current Assets | $56.33M | $81.24K | $70.77K | $77.99K | $136.22K | $71.35K | $77.61K | $83.87K | $90.13K | $96.39K | $102.66K | $108.92K | $130.14K | $167.20K | $73.51M | $73.51M | $73.51M | $- |
| Other Assets | $- | $- | $- | $- | $- | $0 | $- | $-0 | $-0 | $- | $- | $- | $- | $- | $-0 | $- | $-73.51M | $- |
| Total Assets | $6.62B | $6.74M | $12.27M | $14.70M | $12.21M | $14.22M | $16.04M | $18.12M | $5.50M | $6.60M | $4.15M | $7.98M | $2.04M | $5.87M | $73.89M | $74.03M | $4.62M | $3.50M |
| Account Payables | $783.62K | $3.13M | $1.28M | $1.68M | $1.36M | $1.26M | $913.87K | $705.09K | $554.21K | $466.08K | $916.48K | $1.46M | $596.26K | $1.03M | $907.05K | $- | $865.90K | $- |
| Short Term Debt | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $16.75K | $33.02K | $- | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $2.91M | $- | $- | $2.91M | $- | $- | $- | $-2.59M | $- | $- | $- | $- | $- |
| Other Current Liabilities | $1.13M | $939.17K | $9.85M | $3.55M | $4.20M | $4.14M | $3.71M | $7.40M | $3.90M | $3.91M | $5.08M | $6.62M | $1.53M | $1.15M | $2.41M | $2.12M | $342.88K | $336.25K |
| Total Current Liabilities | $1.91M | $4.07M | $11.13M | $5.23M | $5.56M | $5.40M | $4.62M | $8.10M | $4.45M | $4.37M | $6.00M | $8.08M | $2.14M | $2.21M | $3.31M | $2.12M | $1.21M | $336.25K |
| Long Term Debt | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $2.91M | $- | $2.91M | $2.91M | $- | $3.15M |
| Total Non-Current Liabilities | $- | $- | $- | $- | $- | $- | $- | $705.09K | $554.21K | $466.08K | $916.48K | $1.46M | $2.91M | $1.06M | $2.91M | $2.91M | $2.91M | $3.15M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $-705.09K | $-554.21K | $-466.08K | $-916.48K | $-1.46M | $-2.91M | $-1.06M | $- | $- | $-2.91M | $- |
| Total Liabilities | $1.91B | $4.07M | $11.13M | $5.23M | $5.56M | $5.40M | $4.62M | $8.10M | $4.45M | $4.37M | $6.00M | $8.08M | $2.14M | $2.21M | $6.22M | $5.03M | $1.21M | $3.49M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $7.48M | $7.48M | $7.48M | $- | $403.73K | $- |
| Common Stock | $522 | $4.29K | $1.64K | $1.63K | $265 | $6.30K | $6.30K | $4.73K | $683 | $23.54K | $15.08K | $15.08K | $2.31K | $2.31K | $73.51M | $73.51M | $2.29K | $2.16K |
| Retained Earnings | $-40.51B | $-38.78M | $-36.54M | $-28.15M | $-25.47M | $-23.26M | $-20.64M | $-19.19M | $-25.35M | $-24.14M | $-22.97M | $-21.13M | $-14.52M | $-10.66M | $-5.85M | $-4.52M | $-2.53M | $-12.19K |
| Accumulated Other Comprehensive Income Loss | $- | $- | $- | $- | $-0 | $0 | $- | $-0 | $- | $- | $- | $- | $62.22M | $- | $0 | $- | $- | $- |
| Other Total Stockholders Equity | $45.21B | $41.45M | $37.68M | $37.62M | $32.11M | $32.08M | $32.04M | $29.20M | $26.40M | $26.34M | $21.11M | $21.02M | $14.42M | $6.83M | $-7.48M | $- | $5.54M | $22.84K |
| Total Stockholders Equity | $4.71B | $2.67M | $1.14M | $9.47M | $6.65M | $8.82M | $11.41M | $10.02M | $1.05M | $2.23M | $-1.84M | $-98.51K | $-99.47K | $3.66M | $67.66M | $69.00M | $3.41M | $12.81K |
| Total Equity | $4.71B | $2.67M | $1.14M | $9.47M | $6.65M | $8.82M | $11.41M | $10.02M | $1.05M | $2.23M | $-1.84M | $-98.51K | $-99.47K | $3.66M | $67.66M | $69.00M | $3.41M | $12.81K |
| Total Liabilities and Stockholders Equity | $6.62B | $6.74M | $12.27M | $14.70M | $12.21M | $14.22M | $16.04M | $18.12M | $5.50M | $6.60M | $4.15M | $7.98M | $2.04M | $5.87M | $73.89M | $74.03M | $4.62M | $3.50M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $6.62B | $6.74M | $12.27M | $14.70M | $12.21M | $14.22M | $16.04M | $18.12M | $5.50M | $6.60M | $4.15M | $7.98M | $2.04M | $5.87M | $73.89M | $74.03M | $4.62M | $3.50M |
| Total Investments | $6.49B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $48.30M | $73.54M | $73.82M | $73.90M | $525.29K | $- |
| Total Debt | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $16.75K | $33.02K | $- | $- | $- | $- |
| Net Debt | $-6.50M | $-6.54M | $-12.07M | $-14.55M | $-11.99M | $-13.99M | $-15.71M | $-17.70M | $-5.25M | $-6.20M | $-3.48M | $-7.19M | $-1.26M | $-4.10M | $-6.37M | $-73.51M | $-4.49M | $-3.32M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-15.04B | $-120.25K | $-10.83M | $-11.99M | $-1.63M |
| Depreciation and Amortization | $27.92M | $25.05K | $25.05K | $16.78K | $- |
| Deferred Income Tax | $- | $- | $- | $- | $- |
| Stock Based Compensation | $168.85M | $155.72K | $301.12K | $470.88K | $43.85K |
| Change in Working Capital | $-3.42M | $982.13K | $-730.97K | $356.22K | $-80.50K |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $-576.28K | $749.66K | $-666.04K | $-269.64K | $30.13K |
| Other Working Capital | $-2.85M | $232.47K | $-64.93K | $625.86K | $-80.50K |
| Other Non Cash Items | $-3.48B | $-8.33M | $14.96K | $52.38K | $1.50M |
| Net Cash Provided by Operating Activities | $-18.32B | $-7.29M | $-11.22M | $-11.09M | $-215.07K |
| Investments in Property Plant and Equipment | $-19.17K | $-4 | $- | $-131.96K | $- |
| Acquisitions Net | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $-74.04M |
| Sales Maturities of Investments | $- | $- | $- | $525.29K | $- |
| Other Investing Activities | $-19.15M | $- | $- | $-525.29K | $-74.04M |
| Net Cash Used for Investing Activities | $-19.17M | $- | $- | $-131.96K | $-74.04M |
| Debt Repayment | $- | $- | $-796.88K | $- | $15.00K |
| Common Stock Issued | $5.42M | $14.03M | $4.46M | $600.00K | $74.25M |
| Common Stock Repurchased | $- | $-5.00K | $-7.65M | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $12.84B | $-4.97K | $11.54M | $7.40M | $-65.40M |
| Net Cash Used Provided by Financing Activities | $12.85B | $14.03M | $15.20M | $8.00M | $74.26M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $-74.24M |
| Net Change in Cash | $-5.49B | $6.74M | $3.98M | $-3.22M | $-74.23M |
| Cash at End of Period | $6.50B | $11.99M | $5.25M | $1.27M | $11.73K |
| Cash at Beginning of Period | $11.99B | $5.25M | $1.27M | $4.49M | $74.24M |
| Operating Cash Flow | $-18.32B | $-7.29M | $-11.22M | $-11.09M | $-215.07K |
| Capital Expenditure | $-19.17K | $-4 | $- | $-131.96K | $- |
| Free Cash Flow | $-18.34B | $-7.29M | $-11.22M | $-11.22M | $-215.07K |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | June 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-15.02B | $-11.22M | $-8.39M | $-2.68M | $-2.20M | $-2.63M | $-1.45M | $6.16M | $-1.21M | $-1.17M | $-1.83M | $-6.62M | $-3.86M | $-3.04M | $-2.47M | $-2.61M | $-2.89M | $-164.88K |
| Depreciation and Amortization | $27.89M | $20.70K | $7.22K | $6.26K | $6.26K | $6.26K | $6.26K | $6.26K | $6.26K | $6.26K | $6.26K | $6.26K | $6.26K | $6.07K | $3.81K | $642 | $- | $- |
| Deferred Income Tax | $- | $- | $- | $- | $-15.89K | $-62.96K | $- | $- | $716.01K | $-503.59K | $-647.08K | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $168.66M | $96.28K | $57.09K | $32.09K | $32.09K | $32.10K | $59.44K | $32.09K | $32.36K | $40.67K | $90.19K | $137.89K | $105.91K | $131.32K | $131.32K | $102.33K | $43.85K | $- |
| Change in Working Capital | $-4.41M | $-1.32M | $5.85M | $-126.47K | $229.91K | $965.90K | $-185.90K | $-27.77K | $221.50K | $-607.62K | $-1.97M | $1.63M | $854.66K | $658.11K | $-1.27M | $118.00K | $344.10K | $-65.00K |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $-2.34M | $1.77M | $-400.34K | $321.77K | $28.72K | $343.36K | $208.78K | $168.80K | $70.20K | $-450.39K | $-544.37K | $258.51K | $-434.84K | $124.05K | $-177.61K | $218.75K | $- | $- |
| Other Working Capital | $-2.07M | $-3.08M | $6.25M | $-448.23K | $201.19K | $622.54K | $-394.68K | $-196.57K | $151.29K | $-157.23K | $-1.43M | $1.37M | $1.29M | $534.05K | $-1.10M | $-100.75K | $344.10K | $-65.00K |
| Other Non Cash Items | $-3.48B | $-1.80M | $467.46K | $-345.58K | $-52.31K | $-29.60K | $-423.24K | $-7.74M | $-716.01K | $503.59K | $647.08K | $14.96K | $14.65K | $14.35K | $14.06K | $9.33K | $1.11M | $99.53K |
| Net Cash Provided by Operating Activities | $-18.30B | $-14.22M | $-2.48M | $-2.84M | $-2.00M | $-1.72M | $-1.99M | $-1.58M | $-947.47K | $-1.73M | $-3.71M | $-4.83M | $-2.88M | $-2.23M | $-3.59M | $-2.38M | $-1.39M | $-130.35K |
| Investments in Property Plant and Equipment | $17.69K | $-17.69K | $-19.17K | $-19.17K | $- | $- | $- | $- | $- | $- | $- | $- | $16.15K | $- | $-49.02K | $-99.10K | $- | $- |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-482.87K | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $281.97K | $- | $-281.97K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $525.29K | $281.97K | $71.58K | $134.64K | $- | $- |
| Other Investing Activities | $-19.13M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-525.29K | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $-18.83M | $-17.69K | $-301.14K | $-19.17K | $- | $- | $- | $- | $- | $- | $- | $- | $16.15K | $281.97K | $-49.02K | $-99.10K | $- | $- |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-796.88K | $- | $- | $- | $- | $-275.00K | $- |
| Common Stock Issued | $- | $25.00K | $25.00K | $5.42M | $-14.03M | $- | $15 | $14.03M | $-19.18M | $4.45M | $- | $19.19M | $-600.00K | $- | $- | $600.00K | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $5.00K | $- | $- | $-5.00K | $- | $- | $- | $-7.65M | $-25.70M | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $12.84B | $3.74M | $5.39M | $127 | $14.02M | $- | $15 | $-4.98K | $5.00K | $- | $- | $4.28M | $- | $- | $- | $7.40M | $-3.15M | $1.00M |
| Net Cash Used Provided by Financing Activities | $12.83B | $3.74M | $5.42M | $5.42M | $- | $- | $15 | $14.02M | $5.00K | $4.45M | $- | $10.74M | $-24.92M | $- | $- | $8.00M | $7.87M | $1.00M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $6.81M | $- | $- | $- | $- | $- |
| Net Change in Cash | $-42.03K | $-5.53M | $-2.48M | $2.56M | $-2.00M | $-1.72M | $-1.99M | $12.45M | $-942.47K | $2.72M | $-3.71M | $5.91M | $-2.86M | $-2.23M | $-3.64M | $5.52M | $6.47M | $871.65K |
| Cash at End of Period | $6.50M | $6.54M | $12.07M | $14.55M | $11.99M | $13.99M | $15.71M | $17.70M | $5.25M | $6.20M | $3.48M | $7.19M | $1.27M | $4.14M | $6.37M | $10.02M | $6.47M | $871.65K |
| Cash at Beginning of Period | $6.54M | $12.07M | $14.55M | $11.99M | $13.99M | $15.71M | $17.70M | $5.25M | $6.20M | $3.48M | $7.19M | $1.27M | $4.14M | $6.37M | $10.02M | $4.49M | $- | $- |
| Operating Cash Flow | $-18.30B | $-14.22M | $-2.48M | $-2.84M | $-2.00M | $-1.72M | $-1.99M | $-1.58M | $-947.47K | $-1.73M | $-3.71M | $-4.83M | $-2.88M | $-2.23M | $-3.59M | $-2.38M | $-1.39M | $-130.35K |
| Capital Expenditure | $17.69K | $-17.69K | $-19.17K | $-19.17K | $- | $- | $- | $- | $- | $- | $- | $- | $16.15K | $- | $-49.02K | $-99.10K | $- | $- |
| Free Cash Flow | $-18.32B | $-14.26M | $-2.50M | $-2.86M | $-2.00M | $-1.72M | $-1.99M | $-1.58M | $-947.47K | $-1.73M | $-3.71M | $-4.83M | $-2.86M | $-2.23M | $-3.64M | $-2.48M | $-1.39M | $-130.35K |
Revelation Biosciences Dividends
Explore Revelation Biosciences's dividend history, including dividend yield, payout ratio, and historical payments.
Revelation Biosciences News
Read the latest news about Revelation Biosciences, including recent articles, headlines, and updates.
Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells
SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced Gemini priming attenuates the inflammatory response in human peripheral blood mononuclear cells (PBMCs) exposed to clinically relevant promoter molecules of inflammation. Revelation anticipates demonstrating the same protective effect in patients treated with Gemini in its Phase 1.
Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference
SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced today that James Rolke Revelation's Chief Executive Officer, will participate in a fireside chat at the 37th Annual Roth Conference on Tuesday, March 18, 2025 at 10:00 a.m. PT in Dana Point, CA. The fireside chat will be webcast live here and available on our Investors section of.
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024
SAN DIEGO--(BUSINESS WIRE)---- $REVB #EARNINGS--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three and twelve months ended December 31, 2024 financial results. Corporate Highlights Announced dosing of first patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients Announced start of its PRIME Phase 1b Clinical Study of Gemini in CKD Patients Announced FD.
Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients
SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced dosing of the first patient in the PRIME (PReconditioning IMmunostimulatory Evaluation) Phase 1b clinical study of intravenous single ascending doses of Gemini in patients with Stage 3 and 4 Chronic Kidney Disease (CKD). The US-based, multi-site, placebo-controlled study will enro.
Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval
SAN DIEGO--(BUSINESS WIRE)---- $REVB #GEMINI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced today the Nasdaq Stock Market LLC (“Nasdaq”) formally notified the Company that REVB common stock will continue to be listed and traded on Nasdaq, as Revelation is in compliance with all requirements for continued listing. On January 21, 2025, Revelation announced the commencement.
Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025
SAN DIEGO--(BUSINESS WIRE)---- $REVB #GEMINI--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that, on January 28, 2025, the Company will implement a 1-for-16 reverse split of its common stock following approval at its Special Meeting of Stockholders held on January 17, 2025. The reverse stock split will be effective as of the morning of January 28, 2025, and the Company's common stock will trade on a post-split basis at the beginning of trading on the same date under.
Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients
SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, announced today that it has started its PRIME (PReconditioning IMmunostimulatory Evaluation) Phase 1b clinical study of escalating doses of intravenously administered Gemini in patients with Stage 3 and 4 Chronic Kidney Disease (CKD). The US based multi-site placeb.
Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025
SAN DIEGO--(BUSINESS WIRE)---- $REVB #GEMINI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, wants to remind all shareholders to vote their proxies for the January 17, 2025 special meeting of stockholders. In particular, a vote for Proposal 2, the redomicile of the Company from Delaware to Nevada will save the Company at least $200,000.00 per year in franc.
Nasdaq Grants Revelation Biosciences Inc. Continued Listing
SAN DIEGO--(BUSINESS WIRE)---- $REVB #GEMINI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, announced today that the Nasdaq Hearings Panel issued a decision letter granting Revelation's request to continue its listing on The Nasdaq Stock Market, subject to its stock trading at or above $1.00 for at least ten consecutive trading days by February 14, 2025.
Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds
SAN DIEGO--(BUSINESS WIRE)---- $REVB #REVB--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, announced today the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 4,064,040 shares of common stock, issued by the Company on August 22, 2024 (the “Existing Warrants”), at the exercise.
Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND
SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, announced today that the United States Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application for Gemini. This game changing milestone allows the Company to initiate its US based Phase 1b clinical study to evaluate the potent.
Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply
SAN DIEGO--(BUSINESS WIRE)---- $REVB #FDA--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced it has successfully completed the GMP manufacture of Gemini drug product to support anticipated clinical studies in the United States. GMP compliant manufacturing of Gemini is a pivotal requirement for an Investigational New Drug (IND) ap.
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024
SAN DIEGO--(BUSINESS WIRE)---- $REVB #EARNINGS--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, today reported its three and nine months ended September 30, 2024 financial results. Corporate Highlights Completed GMP manufacture of Gemini clinical drug supply Recei.
Revelation Biosciences' Gemini Induces Dose Dependent Significant Increases in IL-10
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced statistically significant, dose dependent increases of interleukin-10 (IL-10) in response to Gemini treatment, using a high sensitivity analysis. This additional positive data follows the previously reported positive topline data from.
Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced safety and biomarker data for its Phase 1 clinical study (RVL-HV02). The primary endpoint to evaluate the safety and tolerability of escalating doses of Gemini was met and a maximum tolerated dose in healthy volunteers was identified.
Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, announced today that it has completed enrollment and dosing of its first in human Phase 1 clinical study (RVL-HV02). The study, which was conducted in Australia, evaluated escalating doses of intravenously administered Gemini and enrolled 40 healthy.
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its three months ended March 31, 2024 financial results. Results of Operations As of March 31, 2024, Revelation had $14.6 million in cash and cash equivalents, compared to $12.0 million as of December 31, 2023. The increase in cash and.
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its three and twelve months ended December 31, 2023 financial results. Corporate Highlights Completed a $6.2 million public offering. Commencement of first in human Phase 1 clinical study of Gemini at the beginning of March. Oral prese.
Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024)
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”) a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, announced today new preclinical data on the potential therapeutic benefit of Gemini for the prevention of acute kidney injury (AKI) that was presented at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) taking.
Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that, as part of a limited number of accepted abstract authors, the company was invited to give an oral presentation of new preclinical data on the potential therapeutic benefit of Gemini for the prevention of acute kidney injury (AKI) at The 29th International Conference on Advances in Critical Care Nephrology taking place in San Diego from March 12-15, 2024. Gemini is the Co.
Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced the closing on February 5, 2024 of its previously announced public offering of 128,470 shares of its common stock and 1,236,530 pre-funded warrants to purchase shares of common stock, together with warrants to purchase up to 2,730,000 shares of its c.
Why Is Revelation Biosciences (REVB) Stock Down 62% Today?
Revelation Biosciences (NASDAQ: REVB ) stock is falling on Thursday after the life sciences company announced pricing for a public offering of its shares. Revelation Biosciences is selling 1,365,000 shares of REVB stock combined with warrants for another 2,730,000 shares.
Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced the pricing of a public offering of 1,365,000 shares of its common stock (or common stock equivalents), together with warrants to purchase up to 2,730,000 shares of its common stock at an offering price to the public of $4.53 per share and associated.
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that new preclinical data on the potential therapeutic benefit of Gemini for the prevention of acute kidney injury (AKI) will be presented at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) taking place in San Diego (March 12-15, 2024). Gemini is the Company's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®), a.
Why Is Revelation Biosciences (REVB) Stock Up 61% Today?
Revelation Biosciences (NASDAQ: REVB ) stock is rising higher on Monday after the clinical-stage biopharmaceutical company's shares underwent a reverse stock split last week. That reverse stock split went into effect on Thursday and resulted in 30 of the company's shares being consolidated into a single share.
Revelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that, on January 25, 2024, the Company will implement a 1-for-30 reverse split of its common stock following approval at its Special Meeting of Stockholders held on January 17, 2024. The reverse stock split will be effective as of the morning of January 25, 2024, and the Company's common stock will trade on a post-split basis at the beginning of trading on the same date under.
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its three and nine months ended September 30, 2023 financial results. Corporate Highlights Recently released biomarker data demonstrating the pharmacologic activity of Gemini in multiple preclinical studies including: Significant mobilization and upr.
Gemini Induces Pharmacologic Activity and Related Physiologic Changes in Multiple Preclinical Studies
SAN DIEGO--(BUSINESS WIRE)-- #biotechnews--Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that data from recent preclinical studies of the Company's Gemini formulation demonstrated its therapeutic potential as a preventative therapy across multiple indications including infection and acute kidney injury. Data, discussed below, highlights the significant pharmacologic activity following administration of Gemini in healthy animals. Additional nonclinical biomarker an.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for REVB.